Cargando…
Remarkable Response to Neoadjuvant Therapy with Methotrexate, Vinblastine, Adriamycin, and Cisplatin for Undifferentiated Bladder Carcinoma: A Case Report and Literature Review
We report a case of primary undifferentiated bladder carcinoma, which revealed a remarkable response to methotrexate, vinblastine, adriamycin, and cisplatin (MVAC) therapy. A 46-year-old Japanese woman presented at the hospital with the chief complaints of gross hematuria and pain during urination....
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264512/ https://www.ncbi.nlm.nih.gov/pubmed/25520650 http://dx.doi.org/10.1159/000369004 |
_version_ | 1782348758857547776 |
---|---|
author | Numahata, Kenji Hoshi, Senji Hoshi, Kiyotsugu Yasuno, Nobuhiro Kubo, Maiko Sasagawa, Isoji Ohta, Shoichiro |
author_facet | Numahata, Kenji Hoshi, Senji Hoshi, Kiyotsugu Yasuno, Nobuhiro Kubo, Maiko Sasagawa, Isoji Ohta, Shoichiro |
author_sort | Numahata, Kenji |
collection | PubMed |
description | We report a case of primary undifferentiated bladder carcinoma, which revealed a remarkable response to methotrexate, vinblastine, adriamycin, and cisplatin (MVAC) therapy. A 46-year-old Japanese woman presented at the hospital with the chief complaints of gross hematuria and pain during urination. Cystoscopy revealed a large smooth-surfaced tumor in the urinary bladder. The histopathological diagnosis was undifferentiated carcinoma. The patient then received 3 courses of MVAC over a 3-month period. Hydronephrosis disappeared after the first course, and the tumor shrank rapidly. After completion of the third MVAC course, radical cystectomy and ileal conduit surgery were performed. After 7 years, the patient has still had no recurrences or metastases. We retrospectively review the relative efficacy of the two popular chemotherapeutic regimens in the management of muscle-invasive bladder cancer in patients who had had radical cystectomy. |
format | Online Article Text |
id | pubmed-4264512 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-42645122014-12-17 Remarkable Response to Neoadjuvant Therapy with Methotrexate, Vinblastine, Adriamycin, and Cisplatin for Undifferentiated Bladder Carcinoma: A Case Report and Literature Review Numahata, Kenji Hoshi, Senji Hoshi, Kiyotsugu Yasuno, Nobuhiro Kubo, Maiko Sasagawa, Isoji Ohta, Shoichiro Case Rep Oncol Published online: November, 2014 We report a case of primary undifferentiated bladder carcinoma, which revealed a remarkable response to methotrexate, vinblastine, adriamycin, and cisplatin (MVAC) therapy. A 46-year-old Japanese woman presented at the hospital with the chief complaints of gross hematuria and pain during urination. Cystoscopy revealed a large smooth-surfaced tumor in the urinary bladder. The histopathological diagnosis was undifferentiated carcinoma. The patient then received 3 courses of MVAC over a 3-month period. Hydronephrosis disappeared after the first course, and the tumor shrank rapidly. After completion of the third MVAC course, radical cystectomy and ileal conduit surgery were performed. After 7 years, the patient has still had no recurrences or metastases. We retrospectively review the relative efficacy of the two popular chemotherapeutic regimens in the management of muscle-invasive bladder cancer in patients who had had radical cystectomy. S. Karger AG 2014-11-05 /pmc/articles/PMC4264512/ /pubmed/25520650 http://dx.doi.org/10.1159/000369004 Text en Copyright © 2014 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions. |
spellingShingle | Published online: November, 2014 Numahata, Kenji Hoshi, Senji Hoshi, Kiyotsugu Yasuno, Nobuhiro Kubo, Maiko Sasagawa, Isoji Ohta, Shoichiro Remarkable Response to Neoadjuvant Therapy with Methotrexate, Vinblastine, Adriamycin, and Cisplatin for Undifferentiated Bladder Carcinoma: A Case Report and Literature Review |
title | Remarkable Response to Neoadjuvant Therapy with Methotrexate, Vinblastine, Adriamycin, and Cisplatin for Undifferentiated Bladder Carcinoma: A Case Report and Literature Review |
title_full | Remarkable Response to Neoadjuvant Therapy with Methotrexate, Vinblastine, Adriamycin, and Cisplatin for Undifferentiated Bladder Carcinoma: A Case Report and Literature Review |
title_fullStr | Remarkable Response to Neoadjuvant Therapy with Methotrexate, Vinblastine, Adriamycin, and Cisplatin for Undifferentiated Bladder Carcinoma: A Case Report and Literature Review |
title_full_unstemmed | Remarkable Response to Neoadjuvant Therapy with Methotrexate, Vinblastine, Adriamycin, and Cisplatin for Undifferentiated Bladder Carcinoma: A Case Report and Literature Review |
title_short | Remarkable Response to Neoadjuvant Therapy with Methotrexate, Vinblastine, Adriamycin, and Cisplatin for Undifferentiated Bladder Carcinoma: A Case Report and Literature Review |
title_sort | remarkable response to neoadjuvant therapy with methotrexate, vinblastine, adriamycin, and cisplatin for undifferentiated bladder carcinoma: a case report and literature review |
topic | Published online: November, 2014 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264512/ https://www.ncbi.nlm.nih.gov/pubmed/25520650 http://dx.doi.org/10.1159/000369004 |
work_keys_str_mv | AT numahatakenji remarkableresponsetoneoadjuvanttherapywithmethotrexatevinblastineadriamycinandcisplatinforundifferentiatedbladdercarcinomaacasereportandliteraturereview AT hoshisenji remarkableresponsetoneoadjuvanttherapywithmethotrexatevinblastineadriamycinandcisplatinforundifferentiatedbladdercarcinomaacasereportandliteraturereview AT hoshikiyotsugu remarkableresponsetoneoadjuvanttherapywithmethotrexatevinblastineadriamycinandcisplatinforundifferentiatedbladdercarcinomaacasereportandliteraturereview AT yasunonobuhiro remarkableresponsetoneoadjuvanttherapywithmethotrexatevinblastineadriamycinandcisplatinforundifferentiatedbladdercarcinomaacasereportandliteraturereview AT kubomaiko remarkableresponsetoneoadjuvanttherapywithmethotrexatevinblastineadriamycinandcisplatinforundifferentiatedbladdercarcinomaacasereportandliteraturereview AT sasagawaisoji remarkableresponsetoneoadjuvanttherapywithmethotrexatevinblastineadriamycinandcisplatinforundifferentiatedbladdercarcinomaacasereportandliteraturereview AT ohtashoichiro remarkableresponsetoneoadjuvanttherapywithmethotrexatevinblastineadriamycinandcisplatinforundifferentiatedbladdercarcinomaacasereportandliteraturereview |